NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 01:54 am EST
Share
NKMAX CO., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 0.00002 million compared to KRW 0.00001 million a year ago. Net loss was KRW 41,258.94 million compared to KRW 13,648.6 million a year ago. Basic loss per share from continuing operations was KRW 509 compared to KRW 173.5 a year ago. Diluted loss per share from continuing operations was KRW 509 compared to KRW 173.5 a year ago. Basic loss per share was KRW 509 compared to KRW 173.5 a year ago.
For the nine months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 56,802.22 million compared to KRW 43,711.31 million a year ago. Basic loss per share from continuing operations was KRW 706 compared to KRW 557 a year ago. Diluted loss per share from continuing operations was KRW 706 compared to KRW 557 a year ago. Basic loss per share was KRW 706 compared to KRW 557 a year ago.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 
